Decheng Capital is a global life sciences venture capital firm founded in 2012, headquartered in Menlo Park, CA with offices in Shanghai and New York. The firm provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies, managing over $2.5 billion in AUM.
Deal activity increased 200% year-over-year (3 deals in the last 12 months). Average disclosed round size is $99.1M (across 36 rounds with reported amounts).
Portfolio
31
Fund Size
$700M
Top Stage
Series C
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
38 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Vvivacta biotechnology | Series A | $50M | Apr 2026 |
| SSyneron Bio | Series B | $150M | Mar 2026 |
| EExcellergy Inc. | Series A | $70M | Oct 2025 |
| OOttimo | Series A | $140M | Dec 2024 |
 Aardvark | Series C | $85M | May 2024 |
| NNalu | Series E | $65M | Mar 2024 |
 Firefly Bio | Unknown | $94M | Feb 2024 |
| Firefly Bio | Series A | $94M | Jan 2024 |
| OOttimo | Series A | $140M | Jan 2024 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| AAcelyrin | Series C | $300M | Sep 2022 |
| HHaoxinqing | Series C | $31M | Jan 2021 |
 Genedx | Series C | $121M | Jul 2020 |
 Cue Health | Series C | $100M | Jan 2020 |
 Polares Medical | Series C | $40M | Jan 2020 |
| Genedx | Series B | $120M | Jan 2020 |
| LLynk Pharmaceuticals | Series A | $20M | Jan 2020 |
| KKeChow Pharma | Series C | $45M | Dec 2019 |
| IIMPACT Therapeutics | Series C | $30M | Aug 2018 |
 Terns Pharmaceuticals | Series B | $80M | Jan 2018 |
 Armo BioSciences | Unknown | $67M | Aug 2017 |
| SSentreheart | Series D | $35M | Sep 2016 |
| AAccuraGen | Unknown | $40M | Jun 2016 |
| AAccuraGen | Series B | $40M | Jan 2016 |
Page 1 of 2
Top Co-Investors
OrbiMed13 shared
Samsara BioCapital8 shared
venBio6 shared
Surveyor Capital5 shared
Longitude Capital4 shared
Vivo Capital4 shared
Wellington Management4 shared
Deerfield4 shared
Cowen Healthcare Investments4 shared
Westlake Village BioPartners4 shared
Access Biotechnology4 shared
Tybourne Capital Management4 shared
Novo Capital3 shared
Endeavour Vision3 shared
Medicxi3 shared
Foresite Capital3 shared
Marshall Wace3 shared
Stanford's StartX Fund3 shared
LAV2 shared
Celgene2 shared
Last updated: 8 September 2026